- Home
- ITIC vs MREO Comparison
ITIC vs MREO Comparison
Compare ITIC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- MREO
- Stock Information
- Founded
- ITIC 1972
- MREO 2015
- Country
- ITIC United States
- MREO United Kingdom
- Employees
- ITIC N/A
- MREO N/A
- Industry
- ITIC Specialty Insurers
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- MREO Health Care
- Exchange
- ITIC Nasdaq
- MREO Nasdaq
- Market Cap
- ITIC 440.1M
- MREO 438.8M
- IPO Year
- ITIC N/A
- MREO N/A
- Fundamental
- Price
- ITIC $217.35
- MREO $2.74
- Analyst Decision
- ITIC
- MREO Strong Buy
- Analyst Count
- ITIC 0
- MREO 5
- Target Price
- ITIC N/A
- MREO $7.60
- AVG Volume (30 Days)
- ITIC 76.9K
- MREO 1.4M
- Earning Date
- ITIC 08-05-2025
- MREO 08-12-2025
- Dividend Yield
- ITIC 7.42%
- MREO N/A
- EPS Growth
- ITIC 18.56
- MREO N/A
- EPS
- ITIC 15.69
- MREO N/A
- Revenue
- ITIC $261,197,999.00
- MREO N/A
- Revenue This Year
- ITIC N/A
- MREO N/A
- Revenue Next Year
- ITIC N/A
- MREO $52.34
- P/E Ratio
- ITIC $13.73
- MREO N/A
- Revenue Growth
- ITIC 15.27
- MREO N/A
- 52 Week Low
- ITIC $174.00
- MREO $1.58
- 52 Week High
- ITIC $290.40
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- ITIC 50.56
- MREO 54.81
- Support Level
- ITIC $204.58
- MREO $2.63
- Resistance Level
- ITIC $216.30
- MREO $2.85
- Average True Range (ATR)
- ITIC 5.21
- MREO 0.14
- MACD
- ITIC 2.33
- MREO -0.02
- Stochastic Oscillator
- ITIC 84.05
- MREO 35.50
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).